Concurrent expression of C4.4A and Tenascin-C in tumor cells relates to poor prognosis of esophageal squamous cell carcinoma

Ohtsuka,Masahisa; Yamamoto,Hirofumi; Oshiro,Ryota; Takahashi,Hidekazu; Masuzawa,Toru; Uemura,Mamoru; Haraguchi,Naotsugu; Nishimura,Junichi; Hata,Taishi; Yamasaki,Makoto; Takemasa,Ichiro; Miyata,Hiroshi; Mizushima,Tsunekazu; Takiguchi,Shuji; Doki,Yuichiro; Mori,Masaki

doi:10.3892/ijo.2013.1956

Concurrent expression of C4.4A and Tenascin-C in tumor cells relates to poor prognosis of esophageal squamous cell carcinoma

Authors:
- Masahisa Ohtsuka
- Hirofumi Yamamoto
- Ryota Oshiro
- Hidekazu Takahashi
- Toru Masuzawa
- Mamoru Uemura
- Naotsugu Haraguchi
- Junichi Nishimura
- Taishi Hata
- Makoto Yamasaki
- Ichiro Takemasa
- Hiroshi Miyata
- Tsunekazu Mizushima
- Shuji Takiguchi
- Yuichiro Doki
- Masaki Mori
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Graduated School of Medicine, Osaka University, Osaka 565-0871, Japan
Published online on: May 24, 2013 https://doi.org/10.3892/ijo.2013.1956
Pages: 439-446

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

C4.4A is a glycolipid-anchored membrane protein expressed in several human malignancies. We recently found that C4.4A expression was associated with poor prognosis of esophageal squamous carcinoma cells (ESCCs), but the underlying mechanism is unknown. To uncover this, we performed PCR array analysis using the HCT116 cell line, a positive control for C4.4A expression and we found that Tenascin-C (TNC) among the many adhesion molecules and extracellular matrix proteins was the best candidate for C4.4A molecule induction. Based on in vitro studies using the TE8 esophageal cancer cells, we examined by immunohistochemistry TNC expression in 111 ESCCs. We found that the TNC-positive group (24.3%) had significantly poorer prognosis than the TNC-negative group in 5-year overall survival. We also found there was a significant correlation between TNC and C4.4A in ESCC tissues (P=0.007). Finally, we found that only the double-positive group for C4.4A and TNC had a significantly worse prognosis (P=0.005). Our data suggest that TNC expression in ESCC may in part explain why C4.4A is associated with a poor prognosis of ESCC since TNC can promote invasion and metastasis.

View Figures

View References

1.	Matzku S, Wenzel A, Liu S and Zoller M: Antigenic differences between metastatic and nonmetastatic BSp73 rat tumor variants characterized by monoclonal antibodies. Cancer Res. 49:1294–1299. 1989.PubMed/NCBI
2.	Claas C, Herrmann K, Matzku S, Moller P and Zoller M: Developmentally regulated expression of metastasis-associated antigens in the rat. Cell Growth Differ. 7:663–678. 1996.PubMed/NCBI
3.	Rosel M, Claas C, Seiter S, Herlevsen M and Zoller M: Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor. Oncogene. 17:1989–2002. 1998. View Article : Google Scholar : PubMed/NCBI
4.	Wurfel J, Seiter S, Stassar M, et al: Cloning of the human homologue of the metastasis-associated rat C4.4A. Gene. 262:35–41. 2001. View Article : Google Scholar : PubMed/NCBI
5.	Smith BA, Kennedy WJ, Harnden P, Selby PJ, Trejdosiewicz LK and Southgate J: Identification of genes involved in human urothelial cell-matrix interactions: implications for the progression pathways of malignant urothelium. Cancer Res. 61:1678–1685. 2001.PubMed/NCBI
6.	Hansen LV, Gardsvoll H, Nielsen BS, et al: Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor. Biochem J. 380:845–857. 2004. View Article : Google Scholar : PubMed/NCBI
7.	Konishi K, Yamamoto H, Mimori K, et al: Expression of C4.4A at the invasive front is a novel prognostic marker for disease recurrence of colorectal cancer. Cancer Sci. 101:2269–2277. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Oshiro R, Yamamoto H, Takahashi H, et al: C4.4A is associated with tumor budding and epithelial-mesenchymal transition of colorectal cancer. Cancer Sci. 103:1155–1164. 2012. View Article : Google Scholar : PubMed/NCBI
9.	Yamamoto H, Oshiro R, Ohtsuka M, et al: Distinct expression of C4.4A in colorectal cancer detected by different antibodies. Int J Oncol. 42:197–201. 2013.
10.	Ohtsuka M, Yamamoto H, Masuzawa T, et al: C4.4A is associated with a poor prognosis of esophageal squamous cell carcinoma. Ann Surg Oncol. Feb 24–2013.(Epub ahead of print).
11.	Beiter K, Hiendlmeyer E, Brabletz T, et al: beta-catenin regulates the expression of tenascin-C in human colorectal tumors. Oncogene. 24:8200–8204. 2005.PubMed/NCBI
12.	Oskarsson T, Acharyya S, Zhang XH, et al: Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 17:867–874. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Nagaharu K, Zhang X, Yoshida T, et al: Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol. 178:754–763. 2011. View Article : Google Scholar
14.	O’Connell JT, Sugimoto H, Cooke VG, et al: VEGF-A and Tenascin-C produced by S100A4⁺ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA. 108:16002–16007. 2011.
15.	Orend G and Chiquet-Ehrismann R: Tenascin-C induced signaling in cancer. Cancer Lett. 244:143–163. 2006. View Article : Google Scholar : PubMed/NCBI
16.	De Wever O, Nguyen QD, Van Hoorde L, et al: Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 18:1016–1018. 2004.PubMed/NCBI
17.	Sarkar S, Nuttall RK, Liu S, Edwards DR and Yong VW: Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res. 66:11771–11780. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Hirata E, Arakawa Y, Shirahata M, et al: Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Sci. 100:1451–1459. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Fukunaga-Kalabis M, Martinez G, Nguyen TK, et al: Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene. 29:6115–6124. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Sjoquist KM, Burmeister BH, Smithers BM, et al: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12:681–692. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Stahl M, Walz MK, Stuschke M, et al: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 27:851–856. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Ando N, Kato H, Igaki H, et al: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar
23.	Yamamoto H, Kondo M, Nakamori S, et al: JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Gastroenterology. 125:556–571. 2003.PubMed/NCBI
24.	Hayashi N, Yamamoto H, Hiraoka N, et al: Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology. 34:638–650. 2001. View Article : Google Scholar : PubMed/NCBI
25.	Noura S, Yamamoto H, Ohnishi T, et al: Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol. 20:4232–4241. 2002. View Article : Google Scholar
26.	Ferlay J, Shin H-R, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
27.	Holmes RS and Vaughan TL: Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 17:2–9. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Pas J, Wyszko E, Rolle K, et al: Analysis of structure and function of tenascin-C. Int J Biochem Cell Biol. 38:1594–1602. 2006. View Article : Google Scholar : PubMed/NCBI
29.	Jones FS and Jones PL: The tenascin family of ECM glyco-proteins: structure, function and regulation during embryonic development and tissue remodeling. Dev Dyn. 218:235–259. 2000. View Article : Google Scholar : PubMed/NCBI
30.	Chiquet-Ehrismann R, Kalla P and Pearson CA: Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res. 49:4322–4325. 1989.PubMed/NCBI
31.	Orend G and Chiquet-Ehrismann R: Adhesion modulation by antiadhesive molecules of the extracellular matrix. Exp Cell Res. 261:104–110. 2000. View Article : Google Scholar : PubMed/NCBI
32.	Villuendas R, Steegmann JL, Pollan M, et al: Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia. 20:1047–1054. 2006. View Article : Google Scholar : PubMed/NCBI
33.	Helleman J, Jansen MP, Ruigrok-Ritstier K, et al: Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res. 14:5555–5564. 2008. View Article : Google Scholar : PubMed/NCBI
34.	Calvo A, Catena R, Noble MS, et al: Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 27:5373–5384. 2008. View Article : Google Scholar : PubMed/NCBI